X
Search
X

Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

- test

Circulating Tumor Cell Count May Predict for Overall Survival in Prostate Cancer

Circulating tumor cell (CTC) counts correspond with overall survival (OS) among patients with early-phase metastatic castration-resistant prostate cancer (mCRPC), according to a study... Read More

The Potential of Radium-223 in Modern Prostate Cancer Treatment

The majority of patients with metastatic castration-resistant prostate cancer (CRPC) have evidence of bone metastases. Among available bone-targeted therapies, only radium-223 dichloride... Read More

Enzalutamide May Not Affect Seizure Incidence Among Men With Prostate Cancer, Seizure Risk Factors

Enzalutamide may not increase the incidence of seizure among patients with metastatic castration-resistant prostate cancer (mCRPC) and seizure risk factors,... Read More

Insurance Status, Race Predict Prostate Cancer Outcomes

Caucasian and African American patients with prostate cancer who are insured privately may have different clinical outcomes, but these disparities are less... Read More

Lower Cabazitaxel Dose May Benefit Patients With Prostate Cancer

Reduced-dose cabazitaxel is non-inferior to the standard dose for patients with metastatic castration-resistant prostate cancer (mCRPC) who previously received docetaxel, according to... Read More

Two Additions to Standard of Care in Prostate Cancer May Improve Outcomes

The addition of abiraterone acetate and prednisone (AAP) or docetaxel and prednisone (DocP) to standard of care (SOC) may improve... Read More

Statin-use May Decrease Mortality Risk in Prostate Cancer

Patients who take statins after prostate cancer (PC) diagnosis may have a reduced risk of mortality, according to a study published in... Read More

Abiraterone Plus Prednisone, Androgen-deprivation for Metastatic Prostate Cancer

Newly diagnosed patients with metastatic, castration-sensitive prostate cancer may have significantly prolonged overall survival (OS) and radiographic progression-free survival (PFS)... Read More

Genomic Sequencing May Help To Determine Prognosis in High-risk Prostate Cancer

Genomic testing and immunomodulation may help to improve outcomes among patients with prostate cancer, according to a study published in... Read More

Active Surveillance and Watchful Waiting for Low-Risk Prostate Cancer

Active surveillance and watchful waiting are emerging as important management options for men diagnosed with early-stage prostate cancer. Patients do not,... Read More

1 2 3 4